Sunday, December 21, 2025
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs

Money Compass by Money Compass
December 3, 2025
in PR Newswire
0
Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Accomplished biotech and CRO leader brings 25+ years of global oncology drug development and operational excellence to propel Emerald’s continued growth.

SINGAPORE, Dec. 3, 2025 /PRNewswire/ — Emerald Clinical Trials, a leading global clinical research organization (CRO), today announced the appointment of Luke Gill, MSc, MBA, as Vice President, Global Head of Oncology, Medical & Scientific Affairs. This appointment underscores Emerald’s continued investment in advancing oncology innovation and delivering high-performing, science-driven clinical programs worldwide.

Related posts

Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro

Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro

December 21, 2025
The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup

The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup

December 21, 2025
Emerald Clinical Trials

Luke brings more than 25 years of international experience in oncology drug development, clinical operations, and strategic partnership management across the biotech and CRO sectors. He has led global oncology programs from first-in-human and translational research through pivotal Phase III trials and regulatory submissions, driving operational excellence and scientific rigor throughout the process.

Before joining Emerald, Luke held senior executive roles at leading CROs, overseeing multi-regional oncology portfolios and strategic alliances with major pharmaceutical and biotech partners across the United States, Europe, and Asia-Pacific. He holds an MSc in Neuro and Molecular Pharmacology and an MBA, uniting deep scientific expertise with business and operational leadership.

“Luke’s appointment marks a pivotal step in Emerald’s growth strategy as we expand our oncology capabilities and global footprint,” said Glenn Kerkhof, Chief Executive Officer, Emerald Clinical Trials. “His proven ability to integrate scientific insight with operational excellence will strengthen our partnerships and accelerate delivery for biotech and pharma clients worldwide.”

At Emerald, Luke will lead the continued expansion of the company’s global oncology portfolio, working closely with clinical, medical, regulatory, and business development teams to drive cohesive, high-impact program execution.

“I’m excited to join Emerald at such an inflection point in its journey,” said Luke Gill. “We share a commitment to advancing innovative oncology therapies with agility, integrity, and precision to deliver meaningful progress to patients and partners worldwide.”

About Emerald Clinical Trials
Emerald Clinical Trials is a leading clinical research organization operating worldwide that serves over 100 biotechs, and 6 of the top 10 pharmaceutical companies. Headquartered in Singapore and driven by operational expertise and scientific excellence, the company provides comprehensive clinical trial services to clients globally, offering solutions across all trial phases. For more information, visit www.emeraldclinical.com.

SOURCE Emerald Clinical Trials

​ 

Previous Post

Precision Aviation Group Expands Capabilities for the Rolls-Royce M250/RR300 with the Acquisition of Helicopter Engine Repair Overhaul Services, Inc. (H.E.R.O.S).

Next Post

Averna and Spherea Join Forces to Build a Leading Test & Quality Engineering Systems Integration Organization

Next Post
Averna and Spherea Join Forces to Build a Leading Test & Quality Engineering Systems Integration Organization

Averna and Spherea Join Forces to Build a Leading Test & Quality Engineering Systems Integration Organization

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro
  • The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup
  • The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved